Erratum: Corrigendum to “Neuroprotective and anti-inflammatory properties of a novel non-thiazolidinedione PPARγ agonist in vitro and in MPTP-treated mice” (Neuroscience (2015) 302 (23–35)(S030645221500367X)(10.1016/j.neuroscience.2015.04.026));Neuroprotective and anti-inflammatory properties of a novel non-thiazolidinedione PPARγ agonist in vitro and in MPTP-treated mice

Neuroscience

Volumn 302, Issue , 2015, Pages 23-35

  Lecca, D ^a   Nevin, D K ^b   Mulas, G ^a   Casu, M A ^c   Diana, A ^a   Rossi, D ^d   Sacchetti, G ^d   Carta, A R ^a  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b TRINITY COLLEGE DUBLIN   (Ireland)

^c INSTITUTE OF TRANSLATIONAL PHARMACOLOGY   (Italy)

^d UNIVERSITY OF FERRARA   (Italy)

Author keywords

Microglia; MPTP; Neuroinflammation; Parkinson; PPAR

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 5 [4 (BENZYLOXY) 3 CHLOROBENZYLIDENE] 2 THIOXODIHYDROPYRIMIDINE 4,6(1H,5H) DIONE; HYDROGEN PEROXIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; LIPOPOLYSACCHARIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; UNCLASSIFIED DRUG; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 5-(4-(BENZYLOXY)-3-CHLOROBENZYLIDENE)DIHYDRO-2-THIOXOPYRIMIDINE-4,6(1H,5H)-DIONE; ANTIDIABETIC AGENT; NEUROPROTECTIVE AGENT; NEUROTOXIN; ROSIGLITAZONE; THIOBARBITURIC ACID DERIVATIVE; TYROSINE 3 MONOOXYGENASE;

AMES TEST; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BACTERIAL STRAIN; BRAIN CELL; CELL VIABILITY; CONTROLLED STUDY; GENOTOXICITY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MICROGLIA; MOUSE; MPTP-INDUCED PARKINSONISM; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PC12 CELL LINE; PRIORITY JOURNAL; RAT; SALMONELLA ENTERICA SEROVAR TYPHIMURIUM; SUBSTANTIA NIGRA PARS COMPACTA; ANIMAL; BRAIN CORTEX; C57BL MOUSE; CELL CULTURE; CHEMICALLY INDUCED; COMPLICATION; CYTOLOGY; DISEASE MODEL; DRUG EFFECTS; ENCEPHALITIS; HUMAN; METABOLISM; NERVE CELL; NEWBORN; PARKINSONISM; PATHOLOGY; WISTAR RAT;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; ANIMALS, NEWBORN; CELLS, CULTURED; CEREBRAL CORTEX; DISEASE MODELS, ANIMAL; ENCEPHALITIS; HUMANS; HYDROGEN PEROXIDE; HYPOGLYCEMIC AGENTS; LIPOPOLYSACCHARIDES; MALE; MICE, INBRED C57BL; NEURONS; NEUROPROTECTIVE AGENTS; NEUROTOXINS; NF-KAPPA B; PARKINSONIAN DISORDERS; RATS; RATS, WISTAR; THIAZOLIDINEDIONES; THIOBARBITURATES; TYROSINE 3-MONOOXYGENASE;

EID: 84938286822     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2016.10.025     Document Type: Erratum

References (63)

1. Barbalat Y., Dombrovskiy V.Y., Weiss R.E. Association between pioglitazone and urothelial bladder cancer. Urology 2012, 80:1-4.
2. Bernardo A., Minghetti L. Regulation of glial cell functions by PPAR-gamma natural and synthetic agonists. PPARRes 2008, 2008:864140.
3. Blesa J., Phani S., Jackson-Lewis V., Przedborski S. Classic and new animal models of Parkinson's disease. J Biomed Biotechnol 2012, 2012:845618.
4. Breidert T., Callebert J., Heneka M.T., Landreth G., Launay J.M., Hirsch E.C. Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease. J Neurochem 2002, 82:615-624.
5. Carta A.R. PPAR-γ: therapeutic prospects in Parkinson's disease. Curr Drug Targets 2013, 14:743-751.
6. Carta A.R., Simuni T. Thiazolidinediones under preclinical and early clinical development for the treatment of Parkinson's disease. Expert Opin Investig Drugs 2014, 17:1-9.
7. Carta A.R., Kachroo A., Schintu N., Xu K., Schwarzschild M.A., Wardas J., Morelli M. Inactivation of neuronal forebrain A receptors protects dopaminergic neurons in a mouse model of Parkinson's disease. J Neurochem 2009, 111:1478-1489.
8. Carta A.R., Frau L., Pisanu A., Wardas J., Spiga S., Carboni E. Rosiglitazone decreases peroxisome proliferator receptor-γ levels in microglia and inhibits TNF-α production: new evidences on neuroprotection in a progressive Parkinson's disease model. Neuroscience 2011, 194:250-261.
9. Cohen S.M. Effects of PPARgamma and combined agonists on the urinary tract of rats and other species. Toxicol Sci 2005, 87:322-327.
10. Cunard R., Ricote M., DiCampli D., Archer D.C., Kahn D.A., Glass C.K., Kelly C.J. Regulation of cytokine expression by ligands of peroxisome proliferator activated receptors. J Immunol 2002, 168:2795-2802.
11. Dehmer T., Heneka M.T., Sastre M., Dichgans J., Schulz J.B. Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation. J Neurochem 2004, 88:494-501.
12. Delerive P., Gervois P., Fruchart J.C., Staels B. Induction of IkappaB alpha expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-alpha activators. J Biol Chem 2000, 275:36703-36707.
13. Desvergne B., Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 1999, 20:649-688.
14. Feinstein D.L., Spagnolo A., Akar C., Weinberg G., Murphy P., Gavrilyuk V., Dello Russo C. Receptor-independent actions of PPAR thiazolidinedione agonists: is mitochondrial function the key?. Biochem Pharmacol 2005, 70:177-188.
15. Hirsch E.C., Hunot S. Neuroinflammation in Parkinson's disease: a target for neuroprotection?. Lancet Neurol 2009, 8:382-397.
16. Home P.D., Pocock S.J., Beck-Nielsen H., Curtis P.S., Gomis R., Hanefeld M., Jones N.P., Komajda M., McMurray J.J. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009, 373:2125-2135. RECORD Study Team.
17. Hunter R.L., Dragicevic N., Seifert K., Choi D.Y., Liu M., Kim H.-C., Cass W.A., Sullivan P.G., Bing G. Inflammation induces mitochondrial dysfunction and dopaminergic neurodegeneration in the nigrostriatal system. J Neurochem 2007, 100:1375-1386.
18. Hunter R.L., Choi D.Y., Ross S.A., Bing G. Protective properties afforded by pioglitazone against intrastriatal LPS in Sprague-Dawley rats. Neurosci Lett 2008, 432:198-201.
19. Ji H., Wang H., Zhang F., Li X., Xiang L., Aiguo S. PPARγ agonist pioglitazone inhibits microglia inflammation by blocking p38 mitogen-activated protein kinase signaling pathways. Inflamm Res 2010, 59:921-929.
20. Kitamura Y., Kakimura J., Matsuoka Y., Nomura Y., Gebicke-Haerter P.J., Taniguchi T. Activators of peroxisome proliferator-activated receptor-gamma (PPARgamma) inhibit inducible nitric oxide synthase expression but increase heme oxygenase-1 expression in rat glial cells. Neurosci Lett 1999, 262:129-132.
21. Kostapanos M.S., Elisaf M.S., Mikhailidis D.P. Pioglitazone and cancer: angel or demon?. Curr Pharm Des 2013, 19:4913-4929.
22. Laloux C., Petrault M., Lecointe C., Devos D., Bordet R. Differential susceptibility to the PPAR-γ agonist pioglitazone in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 6-hydroxydopamine rodent models of Parkinson's disease. Pharmacol Res 2012, 65:514-522.
23. Landreth G., Jiang Q., Mandrekar S., Heneka M. PPARgamma agonists as therapeutics for the treatment of Alzheimer's disease. Neurotherapeutics 2008, 5:481-489.
24. Lee E.Y., Lee J.E., Park J.H., Shin I.C., Koh H.C. Rosiglitazone, a PPAR-γ agonist, protects against striatal dopaminergic neurodegeneration induced by 6-OHDA lesions in the substantia nigra of rats. Toxicol Lett 2012, 213:332-344.
25. Li X., Du J., Xu S., Lin X., Ling Z. Peroxisome proliferator-activated receptor-γ agonist rosiglitazone reduces secondary damage in experimental spinal cord injury. J Int Med Res 2013, 41:153-161.
26. Long-Smith C.M., Sullivan A.M., Nolan Y.M. The influence of microglia on the pathogenesis of Parkinson's disease. Prog Neurobiol 2009, 89:277-287.
27. Lourenco M.V., Ledo J.H. Targeting Alzheimer's pathology through PPARγ signaling: modulation of microglial function. J Neurosci 2013, 33:5083-5084.
28. Luna-Medina R., Cortes-Canteli M., Alonso M., Santos A., Martínez A., Perez-Castillo A. Regulation of inflammatory response in neural cells in vitro by thiadiazolidinones derivatives through peroxisome proliferator-activated receptor gamma activation. J Biol Chem 2005, 280:21453-21462.
29. Maron D.M., Ames B.N. Revised methods for the Salmonella mutagenicity test. Mutat Res 1983, 113:173-215.
30. Moraes L.A., Piqueras L., Bishop-Bailey D. Peroxisome proliferator-activated receptors and inflammation. Pharmacol Ther 2006, 110:371-385.
31. Moreno S., Farioli-Vecchioli S., Cerù M.P. Immunolocalization of peroxisome proliferator-activated receptors and retinoid X receptors in the adult rat CNS. Neuroscience 2004, 123:131-145.
32. Mosley R.L., Hutter-Saunders J.A., Stone D.K., Gendelman H.E. Inflammation and adaptive immunity in Parkinson's disease. Cold Spring Harb Perspect Med 2012, 2:a009381.
33. Mouton P.R. Principles and practices of unbiased stereology: an introduction for bioscientists 2002, The Johns Hopkins Univ. Press, London.
34. Nevin D.K., Peters M.B., Carta G., Fayne D., Lloyd D.G. Integrated virtual screening for the identification of novel and selective peroxisome proliferator-activated receptor (PPAR) scaffolds. J Med Chem 2012, 55:4978-4989.
35. Nolan Y.M., Sullivan A.M., Toulouse A. Parkinson's disease in the nuclear age of neuroinflammation. Trends Mol Med 2013, 19:187-196.
36. Nolte R.T., Wisely G.B., Westin S., Cobb J.E., Lambert M.H., Kurokawa R., Rosenfeld M.G., Willson T.M., Glass C.K., Milburn M.V. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma. Nature 1998, 395:137-143.
37. Ouk T., Potey C., Gautier S., Bastide M., Deplanque D., Staels B., Duriez P., Leys D., Bordet R. PPARs: a potential target for a disease-modifying strategy in stroke. Curr Drug Targets 2013, 14:752-767.
38. Park S.W., Yi J.H., Miranpuri G., Satriotomo I., Bowen K., Resnick D.K., Vemuganti R. Thiazolidinedione class of peroxisome proliferator-activated receptor gamma agonists prevents neuronal damage, motor dysfunction, myelin loss, neuropathic pain, and inflammation after spinal cord injury in adult rats. J Pharmacol Exp Ther 2007, 320:1002-1012.
39. Paxinos G., Franklin K.B. The mouse brain in stereotaxic coordinates 2001, Academic Press, San Diego. 2nd ed.
40. Petroske E., Meredith G.E., Callen S., Totterdell S., Lau Y.S. Mouse model of Parkinsonism: a comparison between subacute MPTP and chronic MPTP/probenecid treatment. Neuroscience 2001, 106:589-601.
41. Pisanu A., Lecca D., Mulas G., Wardas J., Simbula G., Spiga S., Carta A.R. Dynamic changes in pro- and anti-inflammatory cytokines in microglia after PPAR-γ agonist neuroprotective treatment in the MPTPp mouse model of progressive Parkinson's disease. Neurobiol Dis 2014, 71C:280-291.
42. Ramsey C.P., Tansey M.G. A survey from 2012 of evidence for the role of neuroinflammation in neurotoxin animal models of Parkinson's disease and potential molecular targets. Exp Neurol 2014, 256:126-132.
43. Ransohoff R.M., Cardona A.E. The myeloid cells of the central nervous system parenchyma. Nature 2010, 468:253-262.
44. Repetto G., del Peso A., Zurita J.L. Neutral red uptake assay for the estimation of cell viability/cytotoxicity. Nat Protoc 2008, 3:1125-1131.
45. Rossi A., Kapahi P., Natoli G., Takahashi T., Chen Y., Karin M., Santoro M.G. Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IkappaB kinase. Nature 2000, 403(6765):103-108.
46. Sadeghian M., Marinova-Mutafchieva L., Broom L., Davis J.B., Virley D., Medhurst A.D., Dexter D.T. Full and partial peroxisome proliferation-activated receptor-γ agonists, but not δ agonist, rescue of dopaminergic neurons in the 6-OHDA parkinsonian model is associated with inhibition of microglial activation and MMP expression. J Neuroimmunol 2012, 246:69-77.
47. Schapira A.H., Olanow C.W., Greenamyre J.T., Bezard E. Slowing of neurodegeneration in Parkinson's disease and Huntington's disease: future therapeutic perspectives. Lancet 2014, 384:545-555.
48. Schintu N., Frau L., Ibba M., Garau A., Carboni E., Carta A.R. Progressive dopaminergic degeneration in the chronic MPTPp mouse model of Parkinson's disease. Neurotox Res 2009, 16:127-139.
49. Shih A.Y., Imbeault S., Barakauskas V., Erb H., Jiang L., Li P., Murphy T.H. Induction of the Nrf2-driven antioxidant response confers neuroprotection during mitochondrial stress in vivo. J Biol Chem 2005, 280:22925-22936.
50. Skerrett R, Malm T, Landreth G (2014) Nuclear receptors in neurodegenerative diseases. Neurobiol Dis [Epub ahead of print].
51. Straus D.S., Glass C.K. Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms. Trends Immunol 2007, 28:551-558.
52. Straus D.S., Pascual G., Li M., Welch J.S., Ricote M., Hsiang C.H., Sengchanthalangsy L.L., Ghosh G., Glass C.K. 15-Deoxy-delta 12,14-prostaglandin J2 inhibits multiple steps in the NF-kappa B signaling pathway. Proc Natl Acad Sci U S A 2000, 97:4844-4849.
53. Sundararajan S., Jiang Q., Heneka M., Landreth G. PPARgamma as a therapeutic target in central nervous system diseases. Neurochem Int 2006, 49:136-144.
54. Swanson C., Emborg M. Expression of peroxisome proliferator-activated receptor-gamma in the substantia nigra of hemiparkinsonian nonhuman primates. Neurol Res 2014, 36:634-646.
55. Swanson C.R., Joers V., Bondarenko V., Brunner K., Simmons H.A., Ziegler T.E., Kemnitz J.W., Johnson J.A., Emborg M.E. The PPAR-γ agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys. J Neuroinflammation 2011, 8:91.
56. Swanson C.R., Du E., Johnson D.A., Johnson J.A., Emborg M.E. Neuroprotective properties of a novel non-thiazoledinedione partial PPAR- γ agonist against MPTP. PPAR Res 2013, 2013:582809.
57. Tansey M.G., Goldberg M.S. Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention. Neurobiol Dis 2010, 37:510-518.
58. Tseng C.H., Tseng F.H. Peroxisome proliferator-activated receptor agonists and bladder cancer: lessons from animal studies. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 2012, 30:368-402.
59. Tureyen K., Kapadia R., Bowen K.K., Satriotomo I., Liang J., Feinstein D.L., Vemuganti R. Peroxisome proliferator-activated receptor-gamma agonists induce neuroprotection following transient focal ischemia in normotensive, normoglycemic as well as hypertensive and type-2 diabetic rodents. J Neurochem 2007, 101:41-56.
60. Turner R.M., Kwok C.S., Chen-Turner C., Maduakor C.A., Singh S., Loke Y.K. Thiazolidinediones and associated risk of bladder cancer: a systematic review and meta-analysis. Br J Clin Pharmacol 2014, 78:258-273.
61. Varga T., Czimmerer Z., Nagy L. PPARs are a unique set of fatty acid regulated transcription factors controlling both lipid metabolism and inflammation. Biochim Biophys Acta 2011, 1812:1007-1022.
62. Vila M., Vukosavic S., Jackson-Lewis V., Neystat M., Jakowec M., Przedborski S. Alpha-synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP. J Neurochem 2000, 74:721-729.
63. Zhao X., Gonzales N., Aronowski J. Pleiotropic role of PPARγ in intracerebral hemorrhage: an intricate system involving Nrf2, RXR, and NF-κB. CNS Neurosci Ther 2014, 10.1111/cns.12350.